Laura Huppert, MD
@laura_huppert
Breast oncologist @UCSF | Interested in breast cancer clinical/translational research, med ed | Author of Huppert’s Notes | Tweets my own
ID:1255950517471023104
30-04-2020 20:02:01
249 Tweets
1,3K Followers
670 Following
Our latest article on Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer, just published ascopubs.org/doi/10.1200/JC…
Erin Cobain Laura Huppert, MD Peter Beitsch Hope Rugo Dr. Laura Esserman Laura VAN T VEER YaleBreastCancer
So incredibly well-deserved Hope Rugo!!! Your dedication to patients is unparalleled & your contributions to practice-changing clinical research are truly exceptional. And on a personal note, thank you for being the best mentor EVER! You are amazing! UCSF Helen Diller Family Comprehensive Cancer Ctr
Fantastic panel diving deep into the data for SG and Dato-DXd in breast cancer, including a flurry of trials bringing these agents into the frontine metastatic and neoadjuvant space.
Will traditional chemo become a thing of the past?
#DAVAVictoriaADCs
Amazing & powerful talks by brilliant women on this #InternationalWomenDay at #MBCC2024 Hope Rugo Jennifer Litton Laura Huppert, MD @DrHeatherMcArthur
Laura Huppert, MD from UCSF Helen Diller Family Comprehensive Cancer Ctr summarizes systemic therapy for early-stage TNBC with a roadmap of current treatment algorithm and discussion of future directions - opportunities to deescalate/escalate therapy and trials for neoadj and/or adj ADCs under investigation! #MBCC24
Tune in tomorrow for a day of live #MBCC24 coverage, beginning with timely updates from Laura Huppert, MD of UCSF Helen Diller Family Comprehensive Cancer Ctr, who is taking over the OncLive Twitter account to spotlight key updates in the breast cancer space! PER #bcsm #oncology
Excited to speak at this Society for Immunotherapy of Cancer virtual update on advances in immunotherapy for breast cancer. Register now with the link below!
Our retrospective multi-center registry of ADC-after-ADC in HER2-low MBC. Most pts have longer PFS on ADC1 vs 2, but not always (so worth trying!) Tx for highlighting VuMedi & for the awesome collaboration Hope Rugo Reshma Mahtani D Idossa, MD Ruta Rao Sarah Premji & others!
Beautiful presentation by ⭐️ UCSF Helen Diller Family Comprehensive Cancer Ctr fellow Saya Jacob about incidence of delayed IRAEs. Retrospective analysis of 300+ pt- 25% rate delayed toxicity (>90d post-ICI start) & 7.5% post-tx, mostly endocrine. Prior early IRAE= ⬆️ late IRAEs. Need to keep monitoring post ICI!
The following @GRASPTweets scientists have more to share with us today at #SABCS23 :. Laura Huppert, MD @kalinskykevin Matteo Lambertini, MD PhD @USCFCancer @winshipatemory @unigenova